WO2008066704A3 - Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs - Google Patents

Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs Download PDF

Info

Publication number
WO2008066704A3
WO2008066704A3 PCT/US2007/023918 US2007023918W WO2008066704A3 WO 2008066704 A3 WO2008066704 A3 WO 2008066704A3 US 2007023918 W US2007023918 W US 2007023918W WO 2008066704 A3 WO2008066704 A3 WO 2008066704A3
Authority
WO
WIPO (PCT)
Prior art keywords
improving bioavailability
mmmdpb
dmmdpb
dpb
geometric mean
Prior art date
Application number
PCT/US2007/023918
Other languages
English (en)
Other versions
WO2008066704A2 (fr
Inventor
Avraham Yacobi
Daniel Aaron Moros
Derek Ganes
Original Assignee
Taro Pharmaceuticals Usa Inc
Avraham Yacobi
Daniel Aaron Moros
Derek Ganes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceuticals Usa Inc, Avraham Yacobi, Daniel Aaron Moros, Derek Ganes filed Critical Taro Pharmaceuticals Usa Inc
Priority to EP07867444A priority Critical patent/EP2081576A4/fr
Publication of WO2008066704A2 publication Critical patent/WO2008066704A2/fr
Publication of WO2008066704A3 publication Critical patent/WO2008066704A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'administration d'acide 1,3-diméthoxyméthyl-5,5-diphénylbarbiturique et de ses composés apparentés avec des aliments augmente la biodisponibilité de ces composés. Les rapports (à la diète/nourri) pour la moyenne géométrique AUC0-t étaient de 35,6 % (DMMDPB), de 36,6 % (MMMDPB) et de 65,3 % (DPB) et pour la moyenne géométrique Cmax ils étaient de 14,6 % (DMMDPB), de 31,9 % (MMMDPB) et de 62,9 % (DPB). Les uréides cycliques peuvent être administrés à un sujet avant ou après ingestion d'aliment dans une période de temps définie.
PCT/US2007/023918 2006-11-14 2007-11-14 Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs WO2008066704A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07867444A EP2081576A4 (fr) 2006-11-14 2007-11-14 Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85870106P 2006-11-14 2006-11-14
US60/858,701 2006-11-14

Publications (2)

Publication Number Publication Date
WO2008066704A2 WO2008066704A2 (fr) 2008-06-05
WO2008066704A3 true WO2008066704A3 (fr) 2009-04-02

Family

ID=39468451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023918 WO2008066704A2 (fr) 2006-11-14 2007-11-14 Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs

Country Status (3)

Country Link
US (1) US20080132529A1 (fr)
EP (1) EP2081576A4 (fr)
WO (1) WO2008066704A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CL2003002588A1 (es) * 2002-12-11 2005-01-07 Taro Pharmaceuticals Ireland L Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
CN105250316B (zh) * 2015-11-14 2018-01-19 西安力邦制药有限公司 一种含二联苯酚的抗癫痫药物组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628056A (en) * 1983-09-14 1986-12-09 Taro Pharmaceutical Industries Ltd. Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) * 1934-05-22 Cc - phenylethyl - n -
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
US4046894A (en) * 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) * 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) * 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3919427A (en) * 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3904627A (en) * 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) * 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) * 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) * 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) * 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
DE3374684D1 (en) * 1982-08-31 1988-01-07 Daikin Ind Ltd A method to trap the enolate ion of the malonic acid or its derivatives
IT1196500B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5456851A (en) * 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
RU2147584C1 (ru) * 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) * 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
WO1998029408A1 (fr) * 1996-12-26 1998-07-09 Nikken Chemicals Co., Ltd. Derives de n-hydroxyuree et compositions medicinales a base de ces derives
US5756815A (en) * 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US5750766A (en) * 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
EP1051181B1 (fr) * 1997-12-31 2004-03-17 The University Of Kansas Remedes contenant des precurseurs hydrosolubles d'amines tertiaires, et leurs procedes d'obtention
DE69906960T2 (de) * 1998-05-08 2004-01-29 Smithkline Beecham Plc Phenylurea und phenylthio urea derivate
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CL2003002588A1 (es) * 2002-12-11 2005-01-07 Taro Pharmaceuticals Ireland L Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
CA2572797A1 (fr) * 2004-07-02 2006-01-12 Daniella Gutman Procede de preparation d'acide 1-methoxymethyl-5,5-diphenylbarbiturique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628056A (en) * 1983-09-14 1986-12-09 Taro Pharmaceutical Industries Ltd. Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2081576A4 *

Also Published As

Publication number Publication date
EP2081576A2 (fr) 2009-07-29
WO2008066704A2 (fr) 2008-06-05
US20080132529A1 (en) 2008-06-05
EP2081576A4 (fr) 2010-06-30

Similar Documents

Publication Publication Date Title
WO2008063211A3 (fr) Préparations à base de dérivés d'acide 2-hydroxy-5-phénylazobenzoïque et leurs applications
HUS1500030I1 (hu) Eljárás az ospemifene biohasznosulásának javítására
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2008019996A3 (fr) Formulations de flibansérine et leur procédé de fabrication
MY141034A (en) Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use
WO2001044485A8 (fr) Conjugaison d'acides gras et composes associes
AU2003262562A1 (en) Method for the production of polylactide from a solution of lactic acid or one of the derivatives thereof
UA104987C2 (uk) Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
EP1500645A4 (fr) Esters d'acides gras a chaine moyenne astaxanthine, leur procede de production et compositions renfermant ces esters
WO2008000731A3 (fr) Composition pharmaceutique destinée à l'administration par voie orale d'acides gras polyinsaturés oméga et d'au moins un principe actif incompatible avec eux, et procédé de préparation de celle-ci
WO2007144169A3 (fr) Dérivés d'entacapone
WO2006005464A3 (fr) Complements alimentaires
WO2009095624A3 (fr) Procede de preparation d'acides dicafeoylquiniques et leur utilisation dans la lutte contre les pucerons
WO2021013795A3 (fr) Procédé de fabrication de sels de nicotinamide ribofuranoside, sels de nicotinamide ribofuranoside en tant que tels, et leurs utilisations
WO2008066704A3 (fr) Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs
WO2010056039A3 (fr) Préparation pharmaceutique orale de pélubiprofène à taux de dissolution et stabilité améliorés
IL180311A0 (en) Process for the preparation of 4,4-difluoro-3-oxobutanoic acid esters
WO2007113857A3 (fr) Formulation de clopidogrel à libération modifiée
WO2011083402A3 (fr) Compositions à libération immédiate de médicaments labiles acides
WO2008093838A1 (fr) Dérivé de pyridyl imidazolidine ayant un groupe sulfamoyle, et utilisation pharmaceutique de ce dérivé
IL144645A0 (en) Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
WO2003029391A1 (fr) Procede de production de compositions de matiere grasse renfermant de l'acide oleanolique et/ou de l'acide maslinique
WO2010021750A3 (fr) Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer
WO2010105951A3 (fr) Composition comprenant la combinaison de madécassoside, d'une arginine et de polysorbate
WO2000053149A3 (fr) Procede et composition se rapportant a l'administration d'un inhibiteur de la cyclo-oxygenase-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867444

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007867444

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE